Clinical application of pharmacogenetics.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Trends in Molecular Medicine

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1471-4914(01)01986-4PMID 11325631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy

  2000cited by this paper
• The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.

  2000cited by this paper
• Clinical, genetic, and pharmacogenetic applications of the Invader assay.

  1999cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

  1999cited by this paper
• Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports

  1999cited by this paper
• Developments in Quantitative PCR

  1998cited by this paper
• This month in nature biotechnology

  1998cited by this paper
• DNA chips: An array of possibilities

  1998cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

  1997cited by this paper
• Adverse drug events in hospitalized patients.

  1997cited by this paper
• Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays.

  1997cited by this paper
• Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

  1996cited by this paper
• The pharmacogenetics of codeine hypoalgesia.

  1995cited by this paper
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

  1995cited by this paper
• Theory and applications of the polymerase chain reaction.

  1990cited by this paper
• Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism

  1989cited by this paper
• Pharmacogenetic perspectives gained from twin and family studies.

  1989cited by this paper

• From detection to intervention: nanotechnology-driven precision strategies in obesity management

  2026cites this paper
• IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

  2026cites this paper
• Design and Implementation of PharMe: A Mobile Application to Return Pharmacogenomic Test Results to Patients

  2025cites this paper
• Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users

  2025cites this paper
• Pharmacogenetic Testing - Evidence, Challenges, and Pathways to Adoption.

  2025cites this paper
• Single-cell omics: moving towards a new era in ischemic stroke research.

  2025cites this paper
• Bespoke hydroxypropyl methylcellulose-based solid foams loaded with poorly soluble drugs by tunable modular design.

  2025cites this paper
• Change surface regression for nonlinear subgroup identification with application to warfarin pharmacogenomics data.

  2025cites this paper
• Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology

  2025cites this paper
• Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testing

  2025cites this paper
• Acoustic ejection mass spectrometry: the potential for personalized medicine

  2025cites this paper
• Promise of Data-Driven Modeling and Decision Support for Precision Oncology and Theranostics

  2025cites this paper
• Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia—a case report

  2025cites this paper
• Pharmacometabolomics: An emerging platform for understanding the pathophysiological processes and therapeutic interventions.

  2025cites this paper
• Pharmacogenomic testing implementation: Tertiary care center experience and results of a pilot of 512 patients

  2025cites this paper
• Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs

  2025cites this paper
• Current status and prospects of nucleic acid mass spectrometry in clinical pharmacogenomics

  2024cites this paper
• Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

  2024cites this paper
• Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study)

  2024cites this paper
• Estimation of a Generalized Treatment Effect in a Control Group Versus Treatment Group Design

  2024cites this paper
• SAFER: sub-hypergraph attention-based neural network for predicting effective responses to dose combinations

  2024cites this paper
• Relating Macroscopic PET Radiomics Features to Microscopic Tumor Phenotypes Using a Stochastic Mathematical Model of Cellular Metabolism and Proliferation

  2024cites this paper
• A comprehensive preanalytical protocol for fresh solid tumor biospecimens.

  2024cites this paper
• Improved semi-parametric inference for a mixture model of responses from a control versus treatment group trial

  2024cites this paper
• Characterizing the genetic architecture of drug response using gene-context interaction methods

  2024cites this paper
• Clinical impact of pharmacogenetic risk variants in a large chinese cohort

  2024cites this paper
• Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?

  2024cites this paper
• SAFER: sub-hypergraph attention-based neural network for predicting effective responses to dose combinations

  2024cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in Personalized Medicine: Optimizing Drug Therapy

  2024cites this paper
• Programmed aptamer target chain reaction (ATCR) for smart therapeutic inhibitor development

  2024cites this paper
• Research on Genetic Variant Characteristics in ADME Genes Based on Whole-Exome Sequencing in the Han Chinese Population.

  2024cites this paper
• Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics.

  2024cites this paper
• Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract

  2024cites this paper
• Introduction to Computational Biomedicine.

  2024cites this paper
• Drug screening on digital microfluidics for cancer precision medicine

  2024cites this paper
• Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test

  2024cites this paper
• Integration of pharmacogenomic and pharmacomicrobiomic data for personalized medicine

  2023cites this paper
• An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice

  2023cites this paper
• Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis

  2023cites this paper
• Development of a point-of-care genetic test for effective treatment of ischaemic stroke: an early model-based cost-effectiveness analysis

  2023cites this paper
• Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy

  2023cites this paper
• Structure–activity relationships andz interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

  2023cites this paper
• Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism

  2023cites this paper
• Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs

  2023cites this paper
• Pharmacogenomics: current status and future perspectives

  2023cites this paper
• Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

  2023cites this paper
• Opportunities for precision oncology revealed by whole genome sequencing 10,478 cancers - the UK 100,000 Genomes Project

  2023cites this paper
• Exploring the role of gut microbiota in advancing personalized medicine

  2023cites this paper
• Drug-microbiota interactions: an emerging priority for precision medicine

  2023cites this paper
• Structural variation of the coding and non-coding human pharmacogenome

  2023cites this paper
• Metabolomics as a Critical Tool for Studying Clinical Surgery

  2023cites this paper
• Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study

  2023cites this paper
• Deciphering the genetic landscape of obesity: a data-driven approach to identifying plausible causal genes and therapeutic targets

  2023cites this paper
• Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer

  2022cites this paper
• Early Insights From a Pharmacogenomic-Enriched Comprehensive Medication Management Program Implementation in an Adult Employee Population

  2022cites this paper
• Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders

  2022cites this paper
• Predictive biomarkers and personalised pharmacotherapy.

  2022cites this paper
• PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer’s disease

  2022cites this paper
• Pricing and market entry decisions in personalized medicine

  2022cites this paper
• Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions

  2022cites this paper
• Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy

  2022cites this paper
• Bringing pharmacomicrobiomics to the clinic through well‐designed studies

  2022cites this paper
• A hitchhiker's guide to cancer models.

  2022cites this paper
• Improving the Effectiveness of Healthcare: Diagnosis-Centered Care Vs. Person-Centered Health Promotion, a Long Forgotten New Model

  2022cites this paper
• Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine

  2022cites this paper
• 2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism

  2022cites this paper
• The Promise of Nanotechnology in Personalized Medicine

  2022cites this paper
• Determination of the frequency of ABCB1 gene polymorphisms (C1236T, C3435T) in the population of the Tashkent region of Uzbekistan

  2022cites this paper
• Pharmacogenetics of Drugs Used in the Treatment of Cancers

  2022cites this paper
• Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager

  2022cites this paper
• Statistical Inference for Method of Moments Estimators of a Semi-Supervised Two-Component Mixture Model

  2022cites this paper
• ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

  2022cites this paper
• Concerning Pharmacogenetics, Pharmacogenomics and Personalized Medicine

  2021cites this paper
• Pharmacometabolomics by NMR in Oncology: A Systematic Review

  2021cites this paper
• 2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism

  2021cites this paper
• Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles

  2021cites this paper
• Pharmacogenetics and Forensic Toxicology: A New Step towards a Multidisciplinary Approach

  2021cites this paper
• Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders

  2021cites this paper
• Connected Healthcare: Improving Patient Care using Digital Health Technologies.

  2021cites this paper
• Translational pharmacogenetics: pharmacogenetically driven clinical decision making

  2021cites this paper
• Ilias El Aita_Manufacturing oral solid dosage forms using pressure-assisted microsyringe 3D-printing

  2021cites this paper
• Mass spectrometry based high-throughput bioanalysis of low molecular weight compounds: are we ready to support personalized medicine?

  2021cites this paper
• Leptin and its receptor gene polymorphism as a target for pharmacotherapy in T2DM and COPD

  2021cites this paper
• Treatment resistant depression

  2021cites this paper
• Oncotherapeutics: A General Overview

  2021cites this paper
• Perceptions and Attitudes of Pharmacogenomics Through the Lens of Community Pharmacists and Patients

  2021cites this paper
• A personalized FEM model for reproducible measurement of anti-inflammatory drugs in transdermal administration to knee

  2021cites this paper
• Data-Enriched Edible Pharmaceuticals (DEEP) with Bespoke Design, Dose and Drug Release

  2021cites this paper
• Geographically Precise Public Health: Case of Southern Mozambique

  2021cites this paper
• Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder

  2021cites this paper
• Evaluation of population‐level pharmacogenetic actionability in Alabama

  2021cites this paper
• Reviews Traditional Knowledge-based Medicine : A Review of History , Principles , and Relevance in the Present Context of P 4 Systems Medicine

  2021cites this paper
• Drug Repositioning: Principles, Resources, and Application of Structure-Based Virtual Screening for the Identification of Anticancer Agents

  2021cites this paper
• Полиморфизм 3435c>T гена ABCB1 (rs1045642) не влияет на профиль эффективности и безопасности миртазипина у пациентов с депрессивными расстройствами, коморбидными с алкогольной зависимостью

  2021cites this paper
• Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics

  2021cites this paper
• Nanotools in Customized Drug Delivery System

  2021cites this paper
• Method of Moments Confidence Intervals for a Semi-Supervised Two-Component Mixture Model

  2021cites this paper
• Personalised Medicine in a Post-Genomic Era

  2021cites this paper
• Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.

  2021cites this paper
• Pharmacogenomics in the era of next generation sequencing – from byte to bedside

  2021cites this paper